Moderna's stock fell sharply by 25% following an unauthorized leak of Phase 3 data for its experimental cancer vaccine developed with Merck. The data was expected to be officially presented at a medical conference this weekend. Merck's shares also declined by 1.4% amid the news. This leak could impact investor sentiment ahead of the formal data release and regulatory review.
Following the leak of Phase 3 data for Moderna's cancer vaccine, Moderna's stock on Pluang dropped significantly, trading at USD 190.28 with a 1-day change of -22.59% as of Oct 23, 2026 01:21 WIB. Merck's shares also declined but more modestly, priced at USD 148.44 with a 1-day change of -0.99%. Investor activity on Pluang shows a majority selling Moderna (57%) and Merck (63%), reflecting cautious sentiment.
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
Moderna, known for its mRNA COVID-19 vaccine, is set to reveal full Phase 3 data for its experimental cancer vaccine targeting melanoma. The results, expected this weekend, could mark a breakthrough in cancer treatment using customized mRNA technolog...
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's techno...
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
